Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without Monoclonal Gammopathies
Author:
Open Access
- 27 July 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 146 (2) , 207-214
Abstract
Objectives: Serum free light chain assay is a recommended screening test for monoclonal gammopathies. Anecdotal observations indicated a high rate of false-positive abnormal κ/λ ratios. This study was undertaken to ascertain the magnitude of the false-positive rate and factors contributing to the error rate. Methods: Results of serum protein electrophoresis, serum free light chains, and related tests, usually done for investigation of suspected monoclonal gammopathy, were reviewed retrospectively for 270 patients and 297 observations. Results: Using the conventional κ/λ ratio, 36.4% of the ratios were abnormal, in the absence of monoclonal gammopathy. When the renal κ/λ ratio was used, the rate of abnormal κ/λ ratios was 30.1%. In patients with a γ-globulin concentration of 1.6 g/dL or more, the usual κ/λ ratio was abnormal in 54.8% of the patients. Urine protein electrophoresis was used in 53 (19.6%) instances, whereas bone marrow examination was done in 65 (24.1%) cases. Conclusions: Usual κ/λ ratio was abnormal in 36.4% of the observations in patients without evidence of monoclonal gammopathy, and an abnormal κ/λ ratio should not be used as the sole indicator for diagnosis of neoplastic proliferation of the lympho-plasmacytic system. Hypergammaglobulinemia is associated with a higher rate of false-positive abnormal κ/λ ratios. Examination of urine for monoclonal immunoglobulins may be underused, and recommendations by some to use serum free light chain assay in place of, rather than as an adjunct to, urine electrophoresis are not warranted.Keywords
This publication has 45 references indexed in Scilit:
- Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?F1000 Medicine Reports, 2013
- Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditionsTherapeutic Advances in Hematology, 2012
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple myelomaLeukemia, 2012
- Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patientsLeukemia, 2012
- Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUSLeukemia, 2012
- Use of Nonclonal Serum Immunoglobulin Free Light Chains to Predict Overall Survival in the General PopulationMayo Clinic Proceedings, 2012
- Serum Free Light Chains and the Risk of ESRD and Death in CKDClinical Journal of the American Society of Nephrology, 2011
- Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective studyBlood, 2009
- Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failureBMC Nephrology, 2008
- Tumour markers: An overviewIndian Journal of Clinical Biochemistry, 2007